To include your compound in the COVID-19 Resource Center, submit it here.

Shield falls on Phase III Feraccru miss

Shield Therapeutics plc (LSE:STX) fell 65p (58%) to 47.50p on Monday after reporting that Feraccru ferric maltol missed the primary

Read the full 203 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE